We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Syncona Limited (SYNC) Ordinary NPV

Sell:122.20p Buy:122.80p 0 Change: 0.20p (0.16%)
FTSE 250:0.37%
Market closed Prices as at close on 28 March 2024 Prices delayed by at least 15 minutes | Switch to live prices |
Sell:122.20p
Buy:122.80p
Change: 0.20p (0.16%)
Market closed Prices as at close on 28 March 2024 Prices delayed by at least 15 minutes | Switch to live prices |
Sell:122.20p
Buy:122.80p
Change: 0.20p (0.16%)
Market closed Prices as at close on 28 March 2024 Prices delayed by at least 15 minutes | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.
Open:
122.60p
Trade high:
124.00p
Year high:
162.20p
Estimated NAV:
188.20
Previous close:
122.80p
Trade low:
122.20p
Year low:
105.00p
Premium/Discount:
-34.96%
Previous:
0.40p (0.33%)
Previous:
0.40p
Volume:
632,316
Dividend yield:
n/a
Currency:
GBX
Data delayed by at least 15 minutes.

Price

  • Net Asset Value (NAV)
SYNCONA performance chart

Premium/Discount

SYNCONA performance chart
Full interactive share price and premium / discount charts

Performance

1 week 1W 4.95% 1 year 1Y 16.91%
1 month 1M 1.44% 2 years 2Y 25.03%
3 months 3M 0.81% 3 years 3Y 53.22%
6 months 6M 15.2% 5 years 5Y 49.36%

Performance figures are based on the previous close price. Past performance is not an indication of future performance.

Trust Basics

Benchmark: FTSE 250 TR GBP
Annual management charge: n/a
Performance fee: No
Ongoing charge: 1.74%
Dividend yield: n/a
Dividend frequency: Annually
Total assets: £1,234m
Gross gearing: 0%
Market capitalisation:Market cap.: £803m
Shares in issue: 655.90 million
Legal structure Closed Ended Investment Company
Domicile: Guernsey
ISIN GG00B8P59C08

Dividend information for this stock is not available.

Dividend information for this stock is not available.

Ready to invest?

Invest now

Want to invest?

To buy shares in , you'll need to have an account.

Explore the options

Important Documents



Objective

To achieve superior long-term capital appreciation from its investments. The Company invests in life science businesses and single or multi-asset projects. The Company will target an IRR per share across its investment portfolio of 15% p.a. over the long term. Over time, it is intended that the Company should invest the significant majority of its assets in Life Science Investments.

NET ASSET VALUE (NAV)

Estimated NAV: 188.20
Latest actual NAV: 188.20
Latest actual NAV date: 31 December 2023
Premium/Discount: -34.96%
12m average Premium/Discount: -27.59%
NAV frequency: Quarterly

Recent trade data is unavailable. We will be replacing it, however in the meantime the information is available on the London Stock Exchange website.

Security Weight
Uk Treasury Bills 13.50%
Capital Pool Investment Funds 7.46%
Quell Therapeutics Limited 6.11%
Swan Bio Therapeutics Limited 5.63%
Autolus Therapeutics PLC ADR 4.65%
Anaveon Ag 4.49%
Milestone Payments 3.74%
Legacy Funds 2.99%
O Mass Therapeutics Limited 2.60%
Freeline Therapeutics Holdings PLC ADR 2.42%

Top 10 sectors currently unavailable.

Country Weight
United Kingdom 8.93%

Key Dates

Launch date: 26 October 2012
Financial year end: March
Next AGM: August 2024
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Prices provided by NBTrader. Charts provided by Factset. Dividend data provided by Digital Look. Recent trade data provided by MoneyAM. Trust basics, holding data, key dates, objective and NAV provided by Morningstar.

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.